ROIV250117P15000
- 4.60
- 0.000.00%
Roivant Sciences Newsroom
Unusual Options Activity: MSTR, UBER and Others Attract Market Bets, MSTR V/OI Ratio Reaches 210.3
Vivek Ramaswamy Open to Replacing JD Vance in Senate -- If Offered -- WSJ
Roivant Sciences Increases Stake in Immunovant With $336.9 Million Purchase
BofA Securities Maintains Roivant Sciences(ROIV.US) With Hold Rating
Bank of America Securities Reaffirms Their Hold Rating on Roivant Sciences (ROIV)
Scipher Medicine and Roivant Partner to Bring Precision Medicine Insights to Rheumatology Drug Discovery and Development
Immunovant Announces $450 Million Private Placement
Unusual Options Activity: NVT, PCG and Others Attract Market Bets, NVT V/OI Ratio Reaches 597.2
Arbutus Could Benefit From Big Pharma Bird Flu Vaccines: Jefferies
Express News | Roivant Sciences Ltd : Guggenheim Cuts Target Price to $15 From $16
Why Roivant Sciences Ltd. (ROIV) Is Skyrocketing
Roivant Sciences(ROIV.US) Officer Sells US$4.14 Million in Common Stock
Express News | Form 144 | Roivant Sciences(ROIV.US) Officer Proposes to Sell 4.23 Million in Common Stocks
Insider Sale: Pres&Chief Investment Officer of $ROIV (ROIV) Sells 10,796 Shares
Roivant Sciences(ROIV.US) Officer Sells US$10.64 Million in Common Stock
Express News | Form 144 | Roivant Sciences(ROIV.US) Officer Proposes to Sell 8.28 Million in Common Stocks
Roivant Sciences(ROIV.US) Officer Sells US$4.97 Million in Common Stock
Five Reasons Why UBS Is Overweight the UK
Express News | Form 144 | Roivant Sciences(ROIV.US) Officer Proposes to Sell 4.97 Million in Common Stocks
Roivant Sciences (ROIV) Receives a Buy From Leerink Partners